Last reviewed · How we verify

NCT07394725

Unlocking New Avenues: Azithromycin Vs Erythromycin in Pre-term, Pre-mature Rupture of Membrane Management

Completed Phase 1 Last updated 6 February 2026
What this trial tests

Phase 1 trial testing Erythromycin in Pre-term Premature Rupture of Membranes in 250 participants. Completed in 31 March 2025.

Timeline
1 April 2024
Primary endpoint
31 March 2025
31 March 2025

Quick facts

Lead sponsorDistrict Headquarters Teaching Hospital Sahiwal
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment250
Start date1 April 2024
Primary completion31 March 2025
Estimated completion31 March 2025
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

District Headquarters Teaching Hospital Sahiwal

Who can join

Adults 18 to 40, female only, with Pre-term Premature Rupture of Membranes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized controlled trial at Sahiwal Teaching Hospital (April 2024-March 2025) compared azithromycin and erythromycin for managing preterm premature rupture of membranes (PPROM) in 250 women (28-33+6 weeks gestation). Participants received either azithromycin 500 mg once daily or erythromycin 250 mg every six hours for seven days.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Erythromycin

Trials testing the same drug.

Other District Headquarters Teaching Hospital Sahiwal trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07394725.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing